Industry: Pharmaceuticals, Biotechnology
Liponex is a biopharmaceutical company moving into Phase II trials with CRD5, its lead candidate. CRD5 raises High Density Lipoprotein (HDL), often called “good cholesterol”. Novel HDL therapies, such as CRD5, are an area of significant interest for pharmaceutical companies worldwide. Liponex also has a broad pipeline of products with drug candidates in areas such as atherosclerosis, cancer, and infectious disease. The goal of Liponex is to continue to develop our proprietary technologies to fight human disease. Our mission is to derive value for our shareholders by developing our drug candidates and programs to the point where there is potential for licensing ( www.liponex.ca )
Liponex Inc.
1740 Woodroffe Ave.
Ottawa, Ontario K2G 3R8
Canada
Tel: (613) 274-7809
Fax: (613) 274-3233